PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 70 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $10,309,858 | -40.9% | 3,162,533 | -4.0% | 0.01% | -28.6% |
Q1 2024 | $17,451,114 | +27.4% | 3,292,663 | +4.1% | 0.01% | +16.7% |
Q4 2023 | $13,701,198 | +58.7% | 3,164,249 | -3.6% | 0.01% | +50.0% |
Q3 2023 | $8,635,208 | -20.3% | 3,283,349 | +6.9% | 0.00% | -20.0% |
Q2 2023 | $10,837,291 | +108338.0% | 3,070,054 | -5.1% | 0.01% | 0.0% |
Q1 2023 | $9,994 | -11.7% | 3,234,235 | +20.8% | 0.01% | -16.7% |
Q4 2022 | $11,323 | -99.8% | 2,676,913 | -11.1% | 0.01% | +50.0% |
Q3 2022 | $7,136,000 | +13.0% | 3,011,149 | +35.8% | 0.00% | 0.0% |
Q2 2022 | $6,317,000 | +14.7% | 2,216,644 | +16.0% | 0.00% | +33.3% |
Q1 2022 | $5,506,000 | -5.1% | 1,911,675 | +0.2% | 0.00% | 0.0% |
Q4 2021 | $5,799,000 | -50.4% | 1,907,554 | +14.4% | 0.00% | -57.1% |
Q3 2021 | $11,684,000 | +93.8% | 1,666,785 | +153.8% | 0.01% | +75.0% |
Q2 2021 | $6,028,000 | -20.2% | 656,655 | -15.5% | 0.00% | -20.0% |
Q1 2021 | $7,556,000 | -6.6% | 777,350 | -1.4% | 0.01% | -16.7% |
Q4 2020 | $8,092,000 | -9.4% | 788,700 | -10.9% | 0.01% | -45.5% |
Q3 2020 | $8,933,000 | -26.9% | 885,340 | -24.5% | 0.01% | -35.3% |
Q2 2020 | $12,226,000 | -25.6% | 1,172,180 | -39.8% | 0.02% | -54.1% |
Q1 2020 | $16,440,000 | -3.7% | 1,947,825 | -0.1% | 0.04% | +76.2% |
Q4 2019 | $17,065,000 | +134.0% | 1,950,306 | +187.9% | 0.02% | +75.0% |
Q3 2019 | $7,292,000 | +26.4% | 677,395 | +49.3% | 0.01% | +33.3% |
Q2 2019 | $5,768,000 | -87.9% | 453,831 | -63.1% | 0.01% | -87.5% |
Q1 2019 | $47,650,000 | +75.7% | 1,228,404 | -7.8% | 0.07% | +71.4% |
Q4 2018 | $27,120,000 | +124.9% | 1,332,696 | +406.7% | 0.04% | +180.0% |
Q3 2018 | $12,058,000 | -62.7% | 262,990 | -51.9% | 0.02% | -64.3% |
Q2 2018 | $32,333,000 | +133.5% | 546,630 | +168.7% | 0.04% | +133.3% |
Q1 2018 | $13,845,000 | -55.3% | 203,450 | -35.0% | 0.02% | -58.1% |
Q4 2017 | $30,961,000 | -48.3% | 313,204 | -37.4% | 0.04% | -52.7% |
Q3 2017 | $59,872,000 | -56.7% | 499,973 | -68.4% | 0.09% | -63.2% |
Q2 2017 | $138,412,000 | +284.0% | 1,583,661 | +63.4% | 0.25% | +274.2% |
Q1 2017 | $36,047,000 | +21.6% | 969,005 | +0.3% | 0.07% | +6.5% |
Q4 2016 | $29,648,000 | -29.2% | 965,718 | +54.7% | 0.06% | -11.4% |
Q3 2016 | $41,847,000 | +702.6% | 624,115 | +256.6% | 0.07% | +483.3% |
Q2 2016 | $5,214,000 | -83.4% | 175,000 | -83.7% | 0.01% | -84.8% |
Q1 2016 | $31,441,000 | -70.6% | 1,070,525 | -21.4% | 0.08% | -64.9% |
Q4 2015 | $106,841,000 | +660.8% | 1,362,771 | +631.3% | 0.22% | +733.3% |
Q3 2015 | $14,043,000 | +698.8% | 186,343 | +1137.3% | 0.03% | +800.0% |
Q2 2015 | $1,758,000 | -62.8% | 15,060 | -24.7% | 0.00% | -66.7% |
Q1 2015 | $4,722,000 | -14.6% | 20,000 | -31.5% | 0.01% | -25.0% |
Q4 2014 | $5,529,000 | -62.8% | 29,214 | -87.0% | 0.01% | -71.4% |
Q2 2014 | $14,859,000 | +322.9% | 225,137 | +567.1% | 0.04% | +320.0% |
Q1 2014 | $3,514,000 | +35040.0% | 33,747 | +33647.0% | 0.01% | – |
Q4 2013 | $10,000 | -99.6% | 100 | -99.8% | 0.00% | -100.0% |
Q3 2013 | $2,329,000 | -56.1% | 43,411 | -63.7% | 0.01% | -56.2% |
Q2 2013 | $5,309,000 | – | 119,645 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lamond Capital Partners LLC | 220,780 | $17,309,000 | 8.63% |
HARVARD MANAGEMENT CO INC | 600,000 | $47,040,000 | 4.58% |
Orbimed Advisors | 2,238,825 | $175,524,000 | 1.59% |
CORNERSTONE CAPITAL MANAGEMENT LLC | 477,005 | $37,397,000 | 1.53% |
WEATHERBIE CAPITAL, LLC | 158,475 | $12,424,000 | 1.46% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $445,835,000 | 1.17% |
BB BIOTECH AG | 431,991 | $33,868,000 | 0.95% |
Grantham, Mayo, Van Otterloo & Co. LLC | 2,899,776 | $227,342,000 | 0.82% |
Tekla Capital Management LLC | 260,200 | $20,400,000 | 0.74% |
Capital International Sarl | 108,005 | $8,468,000 | 0.72% |